He has an open short position for 100 shares and he is losing sleep over it!
Analyst Dan Leonard commented, "We are initiating coverage of San Diego, CA-based Trovagene (TROV) with an Outperform rating and a $9 price target. TROV is an early stage pure play in the cancer liquid biopsy market, a market with the potential in our view to be the largest in molecular diagnostics."
The analyst said the market opportunity could be large. "TROV sits at the forefront of the opportunity to use nextgen sequencing (NGS) to detect cancer markers in biofluids (i.e., liquid biopsy). We believe this type of testing at minimum could complement tissue testing and will likely prove useful in multiple circumstances. While market opportunity assessments for liquid biopsy vary widely, depending on the use case, one can readily envision a market totaling north of $10B long term.
Minn, somebody's buying....either short covering or institutions or both. 1,750,000 shs today ...
that's 1,000,000 over the average trading.
That's all well and good ,MGM BUT ....Where is the bottom? I calculate cash only value @ $2.47/sh.
We sit at $5.61 /sh.after a brutal combination of secondary offering ,short selling, and missed earnings and
market collapse in just 2 weeks time.....
When do we come up for air?
"the half-life of circulating tumor DNA in blood is very short. This means that circulating tumor DNA released from the tumor will quickly leave the bloodstream as it gets filtered into the urine.
To capture sudden tumor dynamic changes in blood, the sampling frequency necessary becomes impractical, and the clinical data is noisy. It's simply impossible to time a blood draw such that one can capture the peak of a wave of circulating tumor DNA.
Our solution again is urine. Rather than taking a snapshot that may or may not capture sudden tumor dynamic changes at this point in time, urine as a sample, captures circulating tumor DNA in the bladder, which accumulates over many hours. If a spike of circulating tumor DNA occur due to massive tumor cell death caused by working therapy, we catch it. It's a simple as that." .......Toni Schuh